What is BioScale?
BioScale, formerly ProterixBio, Inc., operates as a high-complexity CLIA laboratory focused on protein assay development and testing services. The company offers comprehensive end-to-end immuno/protein assay solutions, including the FDA-cleared Presage ST2 Assay for chronic heart failure prognosis. Their client base spans hospital and medical centers, biotech firms, pharmaceutical companies, and diagnostic testing businesses. BioScale's experienced team is dedicated to delivering high-quality protein biomarker data, supporting advanced research and clinical testing needs across various therapeutic areas and specimen types.
How much funding has BioScale raised?
BioScale has raised a total of $116.2M across 5 funding rounds:
Series B
$3M
Series C
$20.7M
Series D
$25M
Unspecified
$18.8M
Series A
$48.7M
Series B (2005): $3M, investors not publicly disclosed
Series C (2007): $20.7M led by Blackfin Technology and F2 Ventures
Series D (2010): $25M, investors not publicly disclosed
Unspecified (2013): $18.8M featuring New Science Ventures, WFD VENTURES, and Morningside Group
Series A (2013): $48.7M backed by New Science Ventures newscienceventures.com and Morningside Ventures morningside.com
Key Investors in BioScale
New Science Ventures
New Science Ventures, LLC (NSV) is a venture capital firm based in Connecticut and London that invests in early and late-stage companies utilizing novel scientific approaches in the life sciences and information technology sectors. The firm focuses on addressing significant unmet needs within these industries.
WFD VENTURES
WFD Ventures LLC provides equity financing and industry expertise to medical device and healthcare technology companies. The principals of WFD have extensive experience commercializing medical technologies and seek partnerships with entrepreneurs, doctors and scientists to improve medical outcomes and maximize the financial potentials of their innovations.
F2 Ventures
F2 Ventures is a healthcare investment platform focused on arbitrage opportunities across the biotech sector, targeting innovation at the right stage for maximum impact.
What's next for BioScale?
With a substantial enterprise-level funding history, BioScale appears to be in a mature stage of development, likely focusing on scaling its operations and expanding its service offerings. The recent major strategic investment suggests a strong validation of its technology and market position. Future endeavors will likely involve further commercialization of its assay development capabilities, potential strategic partnerships, and continued innovation in protein biomarker analysis to address unmet needs in diagnostics and therapeutics.
See full BioScale company page
